Healthcare | August 08, 2021
Metropolis Healthcare PAT at Rs 74.89 crores for Q1FY22
Board approves fundraise of Rs 1500 crore
Board approves fundraise of Rs 1500 crore
Forex gains stood at Rs 20 crore for the quarter
The company expects revenue growth of 10-15 per cent in the US
PAT rises to Rs 195.76 crore
The transaction is expected to close in the Q4FY22
India business contributes to a stellar performance
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Advances deployment of mRNA technology across vaccines and therapeutics development
This robust growth has come despite the raging pandemic for most part of the quarter
Subscribe To Our Newsletter & Stay Updated
